{"id":10320,"date":"2026-09-23T06:37:30","date_gmt":"2026-09-23T11:37:30","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10320"},"modified":"2026-09-23T06:44:02","modified_gmt":"2026-09-23T11:44:02","slug":"nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/","title":{"rendered":"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10320\" class=\"elementor elementor-10320\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget-tablet__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul type=\"disc\"><li><i>Jordi Mones, MD, PhD, to present the first direct-to-Phase 2 randomized, controlled trial data on sonpiretigene isteparvovec optogenetic therapy in macular degeneration<\/i><\/li><li><i>Benjamin Bakall, MD, PhD, to present 4-year REMAIN extension study data on lasting vision improvement with MCO-010 in retinitis pigmentosa<\/i><\/li><li><i>Samarendra Mohanty, PhD, Co-Founder, President and Chief Scientific Officer, to deliver a company presentation at the Retina Forum 2026 in Ophthalmology Futures Forums<\/i><\/li><li><i>Samuel Barone, MD, Chief Medical Officer, to participate in a panel on GA and Intermediate AMD at the Retina Forum 2026 in Ophthalmology Futures Forums<\/i><\/li><\/ul><p><span class=\"legendSpanClass\">\u30c0\u30e9\u30b9<\/span>,\u00a0<span class=\"legendSpanClass\">Sept. 23, 2026<\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/a>, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Jordi Mones, MD, PhD, and Benjamin Bakall, MD, PhD, will present data from Nanoscope&#8217;s geographic atrophies and retinitis pigmentosa programs at the\u00a0<a href=\"https:\/\/euretina.org\/vienna-2026\/\" target=\"_blank\" rel=\"nofollow noopener\"><b>26<\/b><b><sup>\u756a\u76ee<\/sup><\/b><b>\u00a0\u30e6\u30fc\u30ec\u30c6\u30a3\u30ca\u4f1a\u8b70<\/b><\/a><b>, taking place October 1-4, 2026, at the VIECON \u2013 Vienna Congress &amp; Convention Center in Vienna.<\/b>\u00a0The Company also announced that Samarendra Mohanty, Co-Founder, President, and Chief Scientific Officer, and Samuel Barone, the Chief Medical Officer, will deliver a company presentation at the\u00a0<a href=\"https:\/\/www.ophthalmology-futures.com\/retina-forum-2026\/\" target=\"_blank\" rel=\"nofollow noopener\"><b>Retina Forum 2026<\/b><\/a><b>,\u00a0<\/b>\u00a0<b>in the Ophthalmology Futures Forums taking place September 30, 2026,in Vienna.<\/b><\/p><p><b>\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u306e\u8a73\u7d30\uff1a<\/b><\/p><p><a href=\"https:\/\/www.ophthalmology-futures.com\/retina-forum-2026\/\" target=\"_blank\" rel=\"nofollow noopener\"><b>Ophthalmology Futures Forums \u2013 Retina Forum 2026<\/b><\/a><br class=\"dnr\" \/><b>Company Presentation<br class=\"dnr\" \/><\/b><b>\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a\u00a0<\/b>Samarendra Mohanty, PhD, Co-Founder, President, and Chief Scientific Officer<br class=\"dnr\" \/><b>\u65e5\u6642\uff1a\u00a0<\/b>Wednesday, September 30, 2026, 17:50 PM CEST<br class=\"dnr\" \/><b>\u4f4d\u7f6e\uff1a\u00a0<\/b><a href=\"https:\/\/www.imperialridingschool.com\/en\" target=\"_blank\" rel=\"nofollow noopener\">Imperial Riding School<\/a>, Vienna<\/p><p><b>Panel 8:\u00a0<\/b><i>Geographic Atrophy &amp; Intermediate AMD Therapeutics: Regional Evolution of a Global Business<br class=\"dnr\" \/><\/i><b>\u30d1\u30cd\u30ea\u30b9\u30c8\uff1a\u00a0<\/b>\u30b5\u30df\u30e5\u30a8\u30eb\u30fb\u30d0\u30ed\u30fc\u30cd\u533b\u5b66\u535a\u58eb\u3001\u6700\u9ad8\u533b\u7642\u8cac\u4efb\u8005<br class=\"dnr\" \/><b>\u65e5\u6642\uff1a\u00a0<\/b>Wednesday, September 30, 2026, 18:20 PM CEST<br class=\"dnr\" \/><b>\u4f4d\u7f6e\uff1a\u00a0<\/b><a href=\"https:\/\/www.imperialridingschool.com\/en\" target=\"_blank\" rel=\"nofollow noopener\">Imperial Riding School<\/a>, Vienna<\/p><p><a href=\"https:\/\/euretina.org\/vienna-2026\/\" target=\"_blank\" rel=\"nofollow noopener\"><b>26<\/b><b><sup>\u756a\u76ee<\/sup><\/b><b>\u00a0\u30e6\u30fc\u30ec\u30c6\u30a3\u30ca\u4f1a\u8b70<\/b><\/a><br class=\"dnr\" \/><b>\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u30bf\u30a4\u30c8\u30eb:\u00a0<\/b><i>Vision Improvement in Macular Degeneration with Sonpiretigene Isteparvovec Optogenetic Therapy: First Direct-to-Phase 2 Randomized, Controlled Trial<br class=\"dnr\" \/><\/i><b>\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a\u00a0<\/b>Jordi Mones, MD, PhD, Director, Institut de la M\u00e0cula, Barcelona, and member of the Nanoscope Visionary Advisory Committee<br class=\"dnr\" \/><b>\u65e5\u6642\uff1a\u00a0<\/b>Sunday, October 4, 2026, 10:51 AM CEST<br class=\"dnr\" \/><b>\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a\u00a0<\/b>Free Paper 42 \u2013 AMD\/CSC<br class=\"dnr\" \/><b>\u4f4d\u7f6e\uff1a\u00a0<\/b>Free Paper Forum 1<\/p><p><b>Poster Presentation:\u00a0<\/b><i>Optogenetic REMAIN 4-Year Study Data: Lasting Vision Improvement with MCO-010 in the RESTORE Phase 2b\/3 Trial for Retinitis Pigmentosa<br class=\"dnr\" \/><\/i><b>\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a\u00a0<\/b>Benjamin Bakall, MD, PhD, -Director for Clinical Research, Associated Retina Consultants, Phoenix, Arizona, and Assistant Professor, University of Arizona College of Medicine, Phoenix, Arizona<br class=\"dnr\" \/><b>\u65e5\u4ed8\uff1a\u00a0<\/b>Thursday, October 1, 2026<br class=\"dnr\" \/><b>\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a\u00a0<\/b>Inherited Retinal Diseases ePosters (RETINA26-1615)<br class=\"dnr\" \/><b>\u4f4d\u7f6e\uff1a\u00a0<\/b>Poster Hub<\/p><p>These presentations, together with the Company&#8217;s corporate update on\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/09\/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss\/\" target=\"_blank\" rel=\"nofollow noopener\">FDA acceptance of the BLA for MOGENRY\u00ae\u00a0<\/a>\u00a0at the Ophthalmology Futures Forums Retina Forum, highlight the breadth of Nanoscope&#8217;s optogenetic pipeline, spanning the first direct-to-Phase 2 randomized, controlled trial of sonpiretigene isteparvovec in macular degeneration, and continued 4-year durability data from the RESTORE Phase 2b\/3 trial in retinitis pigmentosa.<\/p><p><b>MOGENRY\u00ae\uff08\u30bd\u30f3\u30d4\u30ec\u30c1\u30b2\u30f3\u30fb\u30a4\u30b9\u30c6\u30d1\u30eb\u30dc\u30d9\u30c3\u30af\uff1bMCO-010\uff09\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>Nanoscope&#8217;s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope&#8217;s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY\u00ae is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope&#8217;s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY\u00ae makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY\u00ae does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows.<\/p><p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u308a\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u75be\u60a3\u306e\u7a2e\u985e\u3092\u554f\u308f\u305a\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3092\u5bfe\u8c61\u3068\u3057\u305f\u591a\u65bd\u8a2d\u5171\u540c\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u76f2\u691c\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\u3067\u3042\u308bRESTORE\u7b2c2b\/3\u76f8\u8a66\u9a13\u3067\u826f\u597d\u306a\u7d50\u679c\u304c\u5f97\u3089\u308c\u305f\u3053\u3068\u3092\u53d7\u3051\u3001<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), the\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/09\/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss\/\" target=\"_blank\" rel=\"nofollow noopener\">FDA has accepted and filed the Company&#8217;s BLA for MOGENRY\u00ae<\/a>. If approved, MOGENRY\u00ae has the potential to become the standard of care for patients with RP, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\uff09\u3067\u3042\u308a\u30012026\u5e74\u306b\u7b2c3\u76f8\u767b\u9332\u8a66\u9a13\u3092\u958b\u59cb\u3059\u308b\u4e88\u5b9a\u3067\u3059\u3002MCO-010\u306f\u3001RP\u3068SD\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u304a\u3088\u3073\u30aa\u30fc\u30d5\u30a1\u30f3\u30c9\u30e9\u30c3\u30b0\u6307\u5b9a\u3092\u53d7\u3051\u3066\u304a\u308a\u3001SD\u306b\u3064\u3044\u3066\u306fRMAT\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u975e\u75c7\u5019\u6027\u304a\u3088\u3073\u75c7\u5019\u6027\u306e\u687f\u4f53\u304a\u3088\u3073\u9310\u4f53\u512a\u4f4d\u6027\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3001\u306a\u3089\u3073\u306b\u9ec4\u6591\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3092\u5bfe\u8c61\u3068\u3057\u305fEMA\u306e\u30aa\u30fc\u30d5\u30a1\u30f3\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002MCO-010\u306f\u3001\u65e5\u672c\u3067\u306f\u907a\u4f1d\u6027\u7db2\u819c\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\uff08IRD\uff09\u306e\u5148\u99c6\u3051\u6307\u5b9a\u304a\u3088\u3073\u30aa\u30fc\u30d5\u30a1\u30f3\u6307\u5b9a\u3092\u53d7\u3051\u3066\u304a\u308a\u3001\u30b5\u30a6\u30b8\u30a2\u30e9\u30d3\u30a2\u3067\u306fIRD\u306e\u30aa\u30fc\u30d5\u30a1\u30f3\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u5730\u7406\u7684\u840e\u7e2e\u75c7\u306b\u5bfe\u3059\u308bMCO\u306e\u7b2c2\u76f8\u30d7\u30ed\u30b0\u30e9\u30e0\u306f2026\u5e74\u306b\u958b\u59cb\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3042\u308a\u3001IND\u6e96\u5099\u4e2d\u306e\u4ed6\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u306f\u30ec\u30fc\u30d0\u30fc\u5148\u5929\u6027\u9ed2\u5185\u969c\uff08LCA\uff09\u304c\u542b\u307e\u308c\u307e\u3059\u3002.<\/p><p><b>\u63a5\u89e6\uff1a<\/b><\/p><p>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><u><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/u><\/p><p>\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Jordi Mones, MD, PhD, to present the first direct-to-Phase 2 randomized, controlled trial data on sonpiretigene isteparvovec optogenetic therapy in macular degeneration Benjamin Bakall, MD, PhD, to present 4-year REMAIN extension study data on lasting vision improvement with MCO-010 in retinitis pigmentosa Samarendra Mohanty, PhD, Co-Founder, President and Chief Scientific Officer, to deliver a company presentation at the Retina Forum 2026 in Ophthalmology Futures Forums Samuel Barone, MD, Chief Medical Officer, to participate in a panel on GA and Intermediate AMD at the Retina Forum 2026 in Ophthalmology Futures Forums DALLAS,\u00a0Sept. 23, 2026\u00a0 &#8212; Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10321,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10320","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-23T11:37:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-23T11:44:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum\",\"datePublished\":\"2026-09-23T11:37:30+00:00\",\"dateModified\":\"2026-09-23T11:44:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/\"},\"wordCount\":793,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_Euretina26_Thumb.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/\",\"name\":\"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_Euretina26_Thumb.jpg\",\"datePublished\":\"2026-09-23T11:37:30+00:00\",\"dateModified\":\"2026-09-23T11:44:02+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_Euretina26_Thumb.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_Euretina26_Thumb.jpg\",\"width\":823,\"height\":819},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum - Nanoscope Therapeutics","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-09-23T11:37:30+00:00","article_modified_time":"2026-09-23T11:44:02+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Wilson PJ","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum","datePublished":"2026-09-23T11:37:30+00:00","dateModified":"2026-09-23T11:44:02+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/"},"wordCount":793,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_Euretina26_Thumb.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/","url":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/","name":"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_Euretina26_Thumb.jpg","datePublished":"2026-09-23T11:37:30+00:00","dateModified":"2026-09-23T11:44:02+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_Euretina26_Thumb.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_Euretina26_Thumb.jpg","width":823,"height":819},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"\u30a6\u30a3\u30eb\u30bd\u30f3 PJ"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=10320"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10320\/revisions"}],"predecessor-version":[{"id":10327,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10320\/revisions\/10327"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/10321"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=10320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=10320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=10320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}